BACKGROUND: Familial aggregation of dementia with Lewy bodies (DLB) remains unclear. OBJECTIVES: To determine the degree of family aggregation of DLB by comparing DLB risk between siblings of probands with clinically diagnosed DLB and siblings of probands with clinically diagnosed Alzheimer disease in a cohort of Caribbean Hispanic families and to explore the degree of aggregation of specific clinical manifestations (ie, cognitive fluctuations, visual hallucinations, and parkinsonism) in DLB. DESIGN: Familial cohort study. SETTING: Academic research. PATIENTS: We separately compared risks of possible DLB, probable DLB, and clinical core features of DLB (cognitive fluctuations, visual hallucinations, and parkinsonism) between siblings of probands with clinically diagnosed DLB (n = 344) and siblings of probands with clinically diagnosed Alzheimer disease (n = 280) in 214 Caribbean Hispanic families with extended neurologic and neuropsychological assessment. MAIN OUTCOME MEASURES: We applied general estimating equations to adjust for clustering within families. In these models, age and proband disease status were independent variables, and disease status of siblings was the measure of disease risk and the dependent variable. RESULTS: Compared with siblings of probands having clinically diagnosed Alzheimer disease, siblings of probands having clinically diagnosed DLB had higher risks of probable DLB (odds ratio [OR], 2.29; 95% confidence interval [CI], 1.04-5.04) and visual hallucinations (2.32; 1.16-4.64). They also had increased risks of possible DLB (OR, 1.51; 95% CI, 0.97-2.34) and cognitive fluctuations (1.55; 0.95-2.53). CONCLUSIONS: Dementia with Lewy bodies and core features of DLB aggregate in families. Compared with siblings of probands having clinically diagnosed AD, siblings of probands having clinically diagnosed DLB are at increased risks of DLB and visual hallucinations. These findings are an important step in elucidating the genetic risk factors underlying DLB and in delineating DLB from other neurodegenerative diseases, such as Alzheimer disease.
BACKGROUND:Familial aggregation of dementia with Lewy bodies (DLB) remains unclear. OBJECTIVES: To determine the degree of family aggregation of DLB by comparing DLB risk between siblings of probands with clinically diagnosed DLB and siblings of probands with clinically diagnosed Alzheimer disease in a cohort of Caribbean Hispanic families and to explore the degree of aggregation of specific clinical manifestations (ie, cognitive fluctuations, visual hallucinations, and parkinsonism) in DLB. DESIGN: Familial cohort study. SETTING: Academic research. PATIENTS: We separately compared risks of possible DLB, probable DLB, and clinical core features of DLB (cognitive fluctuations, visual hallucinations, and parkinsonism) between siblings of probands with clinically diagnosed DLB (n = 344) and siblings of probands with clinically diagnosed Alzheimer disease (n = 280) in 214 Caribbean Hispanic families with extended neurologic and neuropsychological assessment. MAIN OUTCOME MEASURES: We applied general estimating equations to adjust for clustering within families. In these models, age and proband disease status were independent variables, and disease status of siblings was the measure of disease risk and the dependent variable. RESULTS: Compared with siblings of probands having clinically diagnosed Alzheimer disease, siblings of probands having clinically diagnosed DLB had higher risks of probable DLB (odds ratio [OR], 2.29; 95% confidence interval [CI], 1.04-5.04) and visual hallucinations (2.32; 1.16-4.64). They also had increased risks of possible DLB (OR, 1.51; 95% CI, 0.97-2.34) and cognitive fluctuations (1.55; 0.95-2.53). CONCLUSIONS:Dementia with Lewy bodies and core features of DLB aggregate in families. Compared with siblings of probands having clinically diagnosed AD, siblings of probands having clinically diagnosed DLB are at increased risks of DLB and visual hallucinations. These findings are an important step in elucidating the genetic risk factors underlying DLB and in delineating DLB from other neurodegenerative diseases, such as Alzheimer disease.
Authors: M X Tang; P Cross; H Andrews; D M Jacobs; S Small; K Bell; C Merchant; R Lantigua; R Costa; Y Stern; R Mayeux Journal: Neurology Date: 2001-01-09 Impact factor: 9.910
Authors: Warren W Barker; Cheryl A Luis; Alice Kashuba; Mercy Luis; Dylan G Harwood; David Loewenstein; Carol Waters; Pat Jimison; Eugene Shepherd; Steven Sevush; Neil Graff-Radford; Douglas Newland; Murray Todd; Bayard Miller; Michael Gold; Kenneth Heilman; Leilani Doty; Ira Goodman; Bruce Robinson; Gary Pearl; Dennis Dickson; Ranjan Duara Journal: Alzheimer Dis Assoc Disord Date: 2002 Oct-Dec Impact factor: 2.703
Authors: Stavra N Romas; Vincent Santana; Jennifer Williamson; Alejandra Ciappa; Joseph H Lee; Haydee Z Rondon; Pedro Estevez; Rafael Lantigua; Martin Medrano; Mayobanex Torres; Yaakov Stern; Benjamin Tycko; Richard Mayeux Journal: Arch Neurol Date: 2002-01
Authors: M P Walker; G A Ayre; J L Cummings; K Wesnes; I G McKeith; J T O'Brien; C G Ballard Journal: Br J Psychiatry Date: 2000-09 Impact factor: 9.319
Authors: P Hollingworth; M L Hamshere; P A Holmans; M C O'Donovan; Rebecca Sims; J Powell; S Lovestone; A Myers; F W DeVrieze; J Hardy; A Goate; M Owen; J Williams Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2007-10-05 Impact factor: 3.568
Authors: Shinsuke Fujioka; Christina Sundal; Audrey J Strongosky; Monica Case Castanedes; Rosa Rademakers; Owen A Ross; Carles Vilariño-Güell; Matthew J Farrer; Zbigniew K Wszolek; Dennis W Dickson Journal: Acta Neuropathol Date: 2012-11-04 Impact factor: 17.088
Authors: Ashley R Winslow; Simon Moussaud; Liya Zhu; Kathryn L Post; Katherine L Post; Dennis W Dickson; Oksana Berezovska; Pamela J McLean Journal: Brain Date: 2014-05-24 Impact factor: 13.501
Authors: M J Keogh; M Kurzawa-Akanbi; H Griffin; K Douroudis; K L Ayers; R I Hussein; G Hudson; A Pyle; H J Cordell; J Attems; I G McKeith; J T O'Brien; D J Burn; C M Morris; A J Thomas; P F Chinnery Journal: Transl Psychiatry Date: 2016-02-02 Impact factor: 6.222